Tenderwize
Retour à la recherche

Open-house rebate agreement for Roxithromycin

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 163 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Roxithromycin, ATC J01FA06

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Mar 31, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Roxithromycin (ATC J01FA06).
  • Supply of authorised and marketable medicinal products in Germany under uniform contract conditions.
Afficher le résumé complet

Open-house supply arrangement for Roxithromycin (ATC J01FA06) pharmaceutical products by AOK Rheinland-Pfalz/Saarland. The notice states that interested pharmaceutical companies may join on equal terms, with no individual negotiations and no selection decision. The contract period runs from 01.06.2025 to 31.05.2027, with monthly entry possible, but the first submission deadline for the initial start date was 30.04.2025. No contract value is stated. The procedure is explicitly described as not constituting a public procurement contract under the procurement rules, although it is published in TED for transparency.

Risques

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only authorised and marketable medicinal products in Germany may be supplied.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show product name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Roxithromycin

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Roxithromycin (ATC J01FA06). The scope excludes paediatric medicines listed in the BfArM list under Section 35(5a) SGB V. Contract terms are uniform for all participants; no individual negotiations are conducted. Contracts can start on the first day of a month within the 24-month period, with a maximum duration of 24 months from the earliest start date. The lot information is explicit in the structured data and notice text.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 31, 2027

Détails de la procédure

Date de publication
10 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
236088-2025

Documents (1)

Appels d'offres similaires